Biotechnology and Pharmaceuticals: Pfizer Withdraws Sickle Cell Disease Treatment
Wednesday, 25 September 2024, 23:01
Pfizer Withdraws Sickle Cell Disease Treatment Oxbryta
In a significant move impacting the biotech and pharmaceuticals sectors, U.S. drugmaker Pfizer Inc. announced on Wednesday the complete withdrawal of its sickle cell disease therapy, Oxbryta. This decision spans all approved markets and entails the cessation of all related studies and access programs.
Implications for the Healthcare Industry
The health care industry is now left grappling with the repercussions of this withdrawal.
- Impact on patients currently using Oxbryta.
- Reassessment of ongoing clinical trials.
- Future strategies for sickle cell disease treatments.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.